Bjørn Simensen ---- Multi Myeloma (IgG lambda) ISS-II

Murakoze! Umurwayi ukomoka muri Noruveje, Bjørn Simensen, umaze imyaka ibiri agize ubumuga.

Umusore w'imyaka 67 witwa Bjørn Simensen yagejejwe mu bitaro muri Nzeri 2017 afite ibibazo by'inkorora n'ububabare mu gatuza. Mu gihe cyo gukora imyitozo ngororamubiri, basanze afite indwara ya myeloma nyinshi (IgG lambda) ISS-II. Umurwayi yahawe imiti ya bortezomib, lenalidomide na dexamethasone inshuro 4. Nyuma y'imiti 4, poroteyine ye ya M yari munsi ya 1g/l. Hanyuma umurwayi yavuye muri lenalidomide (10mg qdx3 byumweru ku kwezi m) yakomeje mu myaka 2 yakurikiyeho. Yakomeje kuba nta ndwara afite kugeza mu mpeshyi ya 2021, ubwo mu gihe cyo gusuzuma indwara yagaragaye ko yari yariyongereyeho poroteyine ya M (5g/l). Lenalidomide yarahagaritswe maze atangira gufata imiti ya carfilzomib na daratumumab kuva mu Ukwakira kugeza Ukuboza 2021. Ariko, imiti ya chimiotherapie ntiyagize ingaruka nziza kandi BM MRD nyuma ya chimiotherapie yari ifite ibimenyetso.

Bwana Bjørn Simensen yagaragaye bwa mbere mu kigo cyacu cya CGT ku ya 14 Gashyantare 2022. BM MRD ye yagaragaje 0.25% by'uturemangingo tw'amaraso tudasanzwe. IEF yagaragaje ko IgG na poroteyine ya M ari 3 g/l. PET-CT Scan yagaragaje ko igitsina cy'intanga cyinjijwe cyane cyane icy'iburyo, nacyo cyarazamutse mu gihe cyo gusuzuma. Hakozwe biopsy y'uturemangingo tw'intanga, igaragaza uturemangingo tw'amaraso twibasira. Umurwayi yatoranijwe kugira ngo ahabwe ubuvuzi bwa CART cell. Hakozwe fludarabine na cyclophosphamide mu gihe cy'iminsi 3. Uturemangingo twa CAR-T twashyizwemo ku munsi wa 0 (4/3/2222). Igipimo cyatanzwe cyari 0.5X10^6 / kg. Nyuma yo guterwa, umurwayi yagize umuriro wa neutropenia wagenzuwe na antibiyotike za iv. Kubyimba kw'uturemangingo tw'iburyo byagabanutse buhoro buhoro kugera ku bunini busanzwe. Ku munsi wa 28 isuzuma rya BM ryagaragaje ko uturemangingo tw'amaraso twagaragaye ko nta turemangingo tw'amaraso twagaragaye. Umurwayi yasezerewe muri Lu Daopei akurikiranwa buri gihe mu kigo cy'amaraso mu mujyi we.